---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-108591"
form_type: "8-K"
ticker: "SRRK"
cik: "0001727196"
company_name: "Scholar Rock Holding Corp"
filed_at: "2023-10-11T23:59:59+00:00"
generated_at: "2026-06-10T01:44:04.208928+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Scholar Rock advances SRK-439 for obesity towards 2025 IND; Phase 2 apitegromab trial in 2024 with mid-2025 data

## Summary
- Plans to file IND for SRK-439, a novel myostatin inhibitor for obesity, in 2025.
- Initiating Phase 2 proof-of-concept trial of apitegromab in combination with GLP-1 RA in obesity in 2024; data expected mid-2025.
- Preclinical data show SRK-439 combined with GLP-1 RA reversed lean mass loss and enhanced fat mass loss in diet-induced obese mice.
- Pivotal Phase 3 SAPPHIRE trial of apitegromab in SMA fully enrolled; topline data expected Q4 2024.
- Leverages selective myostatin inhibition platform; apitegromab already well-tolerated in SMA.

## SEC filing metadata
- accession: 0001104659-23-108591
- form_type: 8-K
- ticker: SRRK
- cik: 0001727196
- company_name: Scholar Rock Holding Corp
- filed_at: 2023-10-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1727196/000110465923108591/0001104659-23-108591-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1727196/000110465923108591/tm2328106d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-108591
- JSON: https://secwatch.observer/filing/0001104659-23-108591.json
- Plain text: https://secwatch.observer/filing/0001104659-23-108591.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.